Réglementation et droit · 30/10/20261 min de lecture
Schedules of Controlled Substances: Placement of Centanafadine in Schedule III
Traduction automatique locale · Langue originale de la source
Résumé
On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and…